Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Toxins produced by C difficile effect disease severity

Research in this week's Lancet shows that the severity of C difficile-associated disease caused by polymerase chain reaction-ribotype 027 could result from hyperproduction of toxins A and B.

News image

Toxins A and B are the primary virulence factors of Clostridium difficile.

Since 2002, an epidemic of C difficile-associated disease with increased morbidity and mortality has been present in Quebec province, Canada.

Dr Michel Warny and colleagues characterized the dominant strain of this epidemic.

The researchers determined whether the dominant strain produces higher amounts of toxins A and B than those produced by non-epidemic strains.

The research team obtained isolates from 124 patients from Centre Hospitalier Universitaire de Sherbrooke in Quebec.

Additional isolates from the USA, Canada, and the United Kingdom were included to increase the genetic diversity of the toxinotypes tested.

The epidemic strain was isolated from 72 with C difficile-associated disease
The Lancet

Isolate characterization included toxinotyping, pulsed-field gel electrophoresis, and polymerase chain reaction ribotyping.

The isolate characterization also included the detection of a binary toxin gene, and detection of deletions in a putative negative regulator for toxins A and B.

By use of an enzyme-linked immunoassay, the team measured the in-vitro production of toxins A and B by epidemic strain and non-dominant strain isolates.

The team found that the epidemic strain was characterized as toxinotype III, and North American pulsed-field gel electrophoresis type 1.

The polymerase chain reaction-ribotype 027 was also characterized by the epidemic strain.

The researchers noted that this strain carried the binary toxin gene cdtB and an 18-bp deletion in a putative negative regulator for toxins A and B.

The research team isolated this strain from 72 patients with C difficile-associated disease.

Peak median toxin A concentrations produced in vitro by polymerase chain reaction-ribotype 027 were 16 times higher than those measured in isolates.

The team observed that peak median toxin B concentrations produced in vitro by polymerase chain reaction-ribotype 027 were 23 times higher than those measured in isolates.

The isolates represented 12 different pulsed-field gel electrophoresis types, known as toxinotype 0.

Dr Warny's team concludes, “The severity of C difficile-associated disease caused by polymerase chain reaction-ribotype 027 could result from hyperproduction of toxins A and B.”

“Dissemination of this strain in North America and Europe could lead to important changes in the epidemiology of C difficile-associated disease.”

Lancet 2005: 366(9491):1079-84
27 September 2005

Go to top of page Email this page Email this page to a colleague

 19 September 2014

Advanced search
 19 September 2014 
Adhesions in abdominal and pelvic surgery
 19 September 2014 
Repeat colonoscopy among US Medicare
 19 September 2014 
Progression to liver cancer in HCV-infected Veterans
 18 September 2014 
Patient improvement following sacral neuromodulation
 18 September 2014 
Autoimmune diseases in functional gastrointestinal disorders
 18 September 2014 
New diagnostic score for hepatic steatosis
 17 September 2014 
Orange juice intake for bowel preparation
 17 September 2014 
Treatment of fistulising perianal Crohn's disease
 17 September 2014 
Interval colorectal cancers
 16 September 2014 
Fiber treats IBS
 16 September 2014 
Resected biliary tract cancer
 16 September 2014 
Postoperative adhesions in digestive surgery
 15 September 2014 
Fecal transplantation for C.diff infection
 15 September 2014 
Prunes and GI function
 15 September 2014 
Antidepressants for IBS
 12 September 2014 
Management of complex colon polyps
 12 September 2014 
Metabolic syndrome delays HBeAg seroclearance
 12 September 2014 
Drug-induced liver disease
 11 September 2014 
Hepatobiliary cirrhosis risk after organ transplant
 11 September 2014 
Sofosbuvir plus peginterferon/ribavirin for HCV
 11 September 2014 
Patient perceptions in celiac disease
 10 September 2014 
Adhesions in abdominal and pelvic surgery
 10 September 2014 
Acute kidney injury after colonoscopy
 10 September 2014 
Management algorithm for endoscopic mucosal resection of colonic lesions
 09 September 2014 
PPIs and spontaneous bacterial peritonitis in cirrhosis
 09 September 2014 
Neutrophil function and mortality in cirrhosis
 09 September 2014 
MELD and liver cancer survival
 08 September 2014 
Vagal nerve blockade and morbid obesity
 08 September 2014 
Comparison of diet programs in overweight and obese adults
 08 September 2014 
Long-term follow-up after bariatric surgery
 05 September 2014 
Healing rates in reflux esophagitis
 05 September 2014 
Progression of environmental enteropathy
 05 September 2014 
Diabetes and liver transplant outcomes
 04 September 2014 
Colectomy rates for refractory ulcerative colitis
 04 September 2014 
Infliximab prevents long-term Crohn’s disease recurrence
 04 September 2014 
Histological recovery with gluten-free diet in celiac disease
 03 September 2014 
Predictors of response in Crohn's disease
 03 September 2014 
Diagnosis of atrophic gastritis
 03 September 2014 
Safety of reinitiation of infliximab therapy
 02 September 2014 
SSRIs and depression in Hep C
 02 September 2014 
Bariatric surgery for obesity
 02 September 2014 
Eosinophilic esophagitis in adults
 01 September 2014 
Risks with anti-TNF in pediatric IBD
 01 September 2014 
Fecal hemoglobin and colorectal cancer screening
 01 September 2014 
Genetic variants in alcoholic liver disease
 29 August 2014 
Gluten-free diet for asymptomatic celiac disease
 29 August 2014 
NSAID-induced small intestinal injury and diaphragm disease
 29 August 2014 
Symptom evaluation in functional dyspepsia
 28 August 2014 
Predictoris of C. diff in out-patients
 28 August 2014 
Detection of gastroesophageal reflux symptoms
 28 August 2014 
Colorectal-cancer mortality after adenoma removal
 27 August 2014 
Endoscopy outcomes in community hospital vs tertiary academic centers
 27 August 2014 
UV exposure and IBD hospitalizations
 27 August 2014 
Hepatocellular carcinoma screening in liver disease
 26 August 2014 
NAFLD and gastroesophageal reflux symptoms
 26 August 2014 
Adalimumab-treated patients with ulcerative colitis
 26 August 2014 
Wound healing after abdominoperineal resection
 25 August 2014 
Surgical management of rectourethral fistulas
 25 August 2014 
Biomarker analysis in biopsies for ulcerative colitis
 25 August 2014 
Ileocolic resection in Crohn's disease

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us